News

Is American Oncology Network (AONC) Fully Valued Following Cencora's $2.4b Buyout Deal?

Cencora (COR) has moved to take control of American Oncology Network (OTCPK:AONC) by signing a deal to acquire the remaining 96% it does not own for an enterprise value of $2.4b. American Oncology Network’s share price has surged in recent weeks, with a 7 day and 30 day share price return of about 100% and a 1 year total shareholder return of 149.26%. This suggests the Cencora offer has sharply reset expectations around the stock’s value and risk profile. Spot similar healthcare momentum by...

Yahoo·20:21COR▼−1.0%

Baird Maintains Outperform on Cencora, Raises Price Target to $375

Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $373 to $375.

Benzinga·03:22COR▼−1.0%

Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology

CONSHOHOCKEN, Pa. & FORT MYERS, Fla., October 21, 2026--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. ("AON") (OTCQX: AONC), a physician-led network of more than 350 oncology providers across 21 states.

Yahoo·07:30COR▼−1.0%

Here’s How Much You Would Have Made Owning Cencora Stock In The Last 5 Years

Cencora (NYSE:COR) has outperformed the market over the past 5 years by 11.54% on an annualized basis producing an average annual return of 22.6%. Currently, Cencora has a market capitalization of $64.88 billion.

Benzinga·07:00COR▼−1.0%

Cencora Agrees To Acquire Remaining Stake In American Oncology Network For $2.4B

Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. ("AON") (OTCQX:AONC), a physician-led network of more than 350 oncology providers across

Benzinga·03:34COR▼−1.0%

Argus Research Maintains Buy on Cencora, Raises Price Target to $380

Argus Research analyst David Toung maintains Cencora (NYSE:COR) with a Buy and raises the price target from $340 to $380.

Benzinga·05:09COR▼−1.0%

Cencora (COR): 3 Reasons We Love This Stock

Cencora has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6% to $341.69 per share while the index has gained 9.7%.

Yahoo·11:55COR▼−1.0%

Is Cencora (COR) Undervalued Or Is Raised Guidance Already Priced In?

Cencora has delivered a powerful long run for shareholders, and the question now is whether the current share price lines up with the cash the business can generate. With cash flows in focus, recent gains invite a closer look at what the underlying economics of the company really support. Over the past 5 years Cencora has returned 192.4%, which puts a lot of accumulated optimism on the line if its future cash generation does not keep pace. Management has highlighted a pharmaceutical centric...

Yahoo·11:11COR▼1.0%

UBS Maintains Buy on Cencora, Lowers Price Target to $400

UBS analyst Kevin Caliendo maintains Cencora (NYSE:COR) with a Buy and lowers the price target from $430 to $400.

Benzinga·09:55COR▼−1.0%

AI Disruption May Benefit Cencora More Than Hims & Hers

Cencora (COR) may gain from AI-driven prescribing volume growth; with strong operating leverage and discounted P/E, see risks and $365 target—read now.

SeekingAlpha·05:38COR▼−1.0%

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.

Yahoo·19:51

If You Invested $1000 In Cencora Stock 10 Years Ago, You Would Have This Much Today

Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.46% on an annualized basis producing an average annual return of 20.2%. Currently, Cencora has a market capitalization of $60.54 billion.

Benzinga·08:30COR▼−1.0%

Cencora Q3 2026 Earnings Call Transcript

Cencora (NYSE:COR) held its third-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire

Benzinga·01:53COR▼−1.0%

Leerink Partners Maintains Outperform on Cencora, Raises Price Target to $388

Leerink Partners analyst Michael Cherny maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $380 to $388.

Benzinga·08:56COR▼−1.0%

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.

Yahoo·09:30

Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs Grow

Despite some market underperformance, Cencora's specific business and macro fundamentals remain supportive. Read why COR stock is a Buy.

SeekingAlpha·23:48COR▼−1.0%

Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release

CONSHOHOCKEN, Pa., October 02, 2026--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.

Yahoo·08:00COR▼−1.0%

Wednesday's session: gap up and gap down stock in the S&P500 index

Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

ChartMill·10:35

$100 Invested In Cencora 5 Years Ago Would Be Worth This Much Today

Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.44% on an annualized basis producing an average annual return of 20.45%. Currently, Cencora has a market capitalization of $57.98 billion.

Benzinga·12:30COR▼−1.0%

Cencora Elects Robert E. Sanchez to Its Board of Directors

CONSHOHOCKEN, Pa., September 25, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026.

Yahoo·08:00COR▼−1.0%

Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027

Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses. Speaking at the Morgan Stanley Global Heal

Yahoo·19:02COR▼−1.0%

Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Offi

Yahoo·06:02COR▼1.0%

Cencora (COR) Lifts EPS Outlook And Buyback, Is The Stock Still Below Fair Value?

Cencora (COR) just combined a stronger fiscal third quarter, a higher full year adjusted EPS outlook, and a US$1b buyback with plans to brief investors at two New York healthcare conferences. Despite the upbeat earnings message, Cencora’s share price has eased in the short term, with a 7 day share price return of down 3.98% and a 30 day share price return of down 2.91% from US$308.78. At the same time, a 90 day share price return of 13.82% and a 1 year total shareholder return of 7.28% sit...

Yahoo·10:08COR▼−1.0%

Cencora (COR) Raised Guidance and Bought Back $1B. What’s the Catch?

On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion […]

Yahoo·08:38COR▼−1.0%

Cencora Tech Chief: AI Is Cutting Some Medical Treatment Decisions in Half

Cencora Global Chief Data and Information Officer Pawan Verma spoke with WSJ Leadership Institute President Alan Murray at the WSJLI Technology Council Summit about how AI is being used in healthcare to speed access to treatment. Verma described a retinal oncology use case in which doctors analyze large volumes of imaging data to determine treatment, saying Cencora is helping cut a decision process that can take 30 to 90 days roughly in half.

Yahoo·15:58COR▼−1.0%

Cencora, Inc. (COR) Presents at 2026 Global Healthcare Conference Transcript

Cencora, Inc. (COR) 2026 Global Healthcare Conference September 15, 2026 3:10 PM EDTCompany ParticipantsEva Boratto - Executive VP & CFORobert Mauch -...

SeekingAlpha·14:01COR▼−1.0%

The Realities of Managing Enterprise AI

A panel of CIOs from Indeed, New York Life and Cencora discuss the risks and advantages of enterprise AI, including operational efficiency, financial waste and the need to implement “control towers” for human oversight of consequential decisions.

Yahoo·10:29COR▼−1.0%

Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cencora, Inc. (COR) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO...

SeekingAlpha·07:01COR▼−1.0%

Cencora (NYSE:COR): A Quality Stock With Strong EBIT Growth and Cash Conversion

Cencora (COR) scores well on EBIT growth, cash-backed profits and debt/FCF, but thin margins and high debt/equity warrant caution for quality investors.

ChartMill·04:11COR▼−1.0%

Is Cencora Stock Underperforming the Dow?

Despite lagging behind the Dow over the past 12 months, Cencora continues to receive a highly bullish outlook from Wall Street analysts.

Yahoo·08:19COR▼−1.0%

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Cencora (NYSE:COR) and its peers.

Yahoo·16:23COR▼−1.0%

Cencora, Inc. (COR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Cencora, Inc. (COR) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 9:30 AM EDTCompany ParticipantsRobert Mauch - President, CEO &...

SeekingAlpha·08:25COR▼−1.0%

RBC Capital Reiterates Sector Perform on Cencora, Maintains $330 Price Target

RBC Capital analyst Ryan Halsted reiterates Cencora (NYSE:COR) with a Sector Perform and maintains $330 price target.

Benzinga·06:37COR▼−1.0%

Here's Why You Should Retain Cencora Stock in Your Portfolio for Now

Cencora's specialty momentum, OneOncology growth and GLP-1 volumes offer upside, but drug-price cuts and MWI risks cloud its outlook.

Yahoo·15:39COR▼−1.0%

Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?

Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·11:30COR▼−1.0%

RBC Capital Initiates Coverage of Cencora (COR) with Sector Perform Recommendation

Fintel·02:44COR▼−1.0%

$100 Invested In Cencora 10 Years Ago Would Be Worth This Much Today

Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.61% on an annualized basis producing an average annual return of 19.99%. Currently, Cencora has a market capitalization of $60.51 billion.

Benzinga·14:00COR▼−1.0%

RBC Capital Initiates Coverage On Cencora with Sector Perform Rating, Announces Price Target of $330

RBC Capital analyst Ryan Halsted initiates coverage on Cencora (NYSE:COR) with a Sector Perform rating and announces Price Target of $330.

Benzinga·05:46COR▼−1.0%

Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity

Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]

Yahoo·08:06COR▼−1.0%

5 Insightful Analyst Questions From Cencora’s Q2 Earnings Call

Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a positive market response. Management credited execution in specialty pharmaceuticals, especially through its Management Services Organizations (MSOs) like OneOncology and RCA, as a core driver of growth, while digital transformation initiatives improved operational efficiency. CEO Robert Mauch highlighted the company’s unique positioning in

Yahoo·03:01

If You Invested $1000 In Cencora Stock 10 Years Ago, You Would Have This Much Today

Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.29% on an annualized basis producing an average annual return of 19.83%. Currently, Cencora has a market capitalization of $59.16 billion.

Benzinga·12:45COR▼−1.0%